micafungin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antifungal antibiotics	1798	235114-32-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: mycamine micafungin micafungin sodium FK-463 FK463	A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS. Molecular weight: 1270.28 Formula: C56H71N9O23S CLOGP: -1.99 LIPINSKI: 3 HAC: 32 HDO: 16 TPSA: 510.14 ALOGS: -3.77 ROTB: 18

Molecule

Description

Molfile Inchi Smiles

Synonyms:

mycamine
micafungin
micafungin sodium
FK-463
FK463

A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.

Molecular weight: 1270.28
Formula: C56H71N9O23S
CLOGP: -1.99
LIPINSKI: 3
HAC: 32
HDO: 16
TPSA: 510.14
ALOGS: -3.77
ROTB: 18

Drug dosage:

Dose	Unit	Route
0.10	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	6.30 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.21 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.17 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.00 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	16 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
March 16, 2005	FDA	FUJISAWA HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	245.06	26.49	155	6710	105390	56179812
Pre-engraftment immune reaction	171.39	26.49	29	6836	209	56284993
Human herpesvirus 6 infection	162.37	26.49	42	6823	2640	56282562
Encephalitis viral	146.16	26.49	35	6830	1600	56283602
Multiple organ dysfunction syndrome	115.95	26.49	75	6790	52695	56232507
Cytomegalovirus test positive	104.40	26.49	30	6835	2796	56282406
Aplastic anaemia	101.76	26.49	39	6826	8889	56276313
Acute graft versus host disease	96.96	26.49	31	6834	4144	56281058
Mucormycosis	96.04	26.49	28	6837	2746	56282456
Aspergillus infection	93.72	26.49	35	6830	7430	56277772
Sepsis	92.66	26.49	99	6766	139741	56145461
Bronchopulmonary aspergillosis	90.26	26.49	35	6830	8229	56276973
Bacterial sepsis	83.63	26.49	27	6838	3722	56281480
Acute graft versus host disease in skin	83.60	26.49	26	6839	3176	56282026
Pneumonia fungal	80.41	26.49	28	6837	4865	56280337
Hepatic function abnormal	73.12	26.49	48	6817	34510	56250692
Septic shock	70.95	26.49	59	6806	60776	56224426
Systemic candida	68.23	26.49	22	6843	3019	56282183
Cytomegalovirus viraemia	67.91	26.49	25	6840	5095	56280107
Thrombotic microangiopathy	65.86	26.49	29	6836	9382	56275820
Cytomegalovirus infection	64.63	26.49	36	6829	19260	56265942
Engraft failure	61.22	26.49	13	6852	342	56284860
Gastrointestinal fungal infection	58.91	26.49	12	6853	256	56284946
Pyrexia	58.03	26.49	145	6720	418628	55866574
Pathogen resistance	57.07	26.49	23	6842	5977	56279225
Meningoencephalitis herpetic	55.85	26.49	15	6850	1089	56284113
Liver abscess	54.21	26.49	18	6847	2708	56282494
Candida infection	52.70	26.49	35	6830	25632	56259570
Respiratory failure	52.06	26.49	61	6804	95001	56190201
Off label use	51.11	26.49	166	6699	556014	55729188
Graft versus host disease	51.04	26.49	22	6843	6759	56278443
Sinus polyp	50.63	26.49	11	6854	323	56284879
Systemic mycosis	50.52	26.49	14	6851	1143	56284059
Enterococcal sepsis	48.59	26.49	14	6851	1316	56283886
Weissella infection	47.47	26.49	7	6858	17	56285185
Product use in unapproved indication	47.16	26.49	71	6794	140751	56144451
Haemophagocytic lymphohistiocytosis	46.76	26.49	23	6842	9549	56275653
Fatigue	43.63	26.49	21	6844	788531	55496671
Aspartate aminotransferase increased	43.55	26.49	52	6813	82550	56202652
Enterobacter infection	42.61	26.49	14	6851	2038	56283164
Fungaemia	42.13	26.49	14	6851	2110	56283092
Platelet count decreased	41.98	26.49	58	6807	106325	56178877
Hypoalbuminaemia	41.68	26.49	22	6843	10577	56274625
Arthralgia	41.47	26.49	6	6859	501663	55783539
Plasma cell leukaemia	41.21	26.49	12	6853	1171	56284031
Geotrichum infection	41.05	26.49	10	6855	491	56284711
Disseminated intravascular coagulation	40.66	26.49	26	6839	17859	56267343
Fungal infection	40.53	26.49	33	6832	32960	56252242
Nasal abscess	40.41	26.49	8	6857	147	56285055
Biloma	40.28	26.49	7	6858	60	56285142
Acute myeloid leukaemia recurrent	38.18	26.49	12	6853	1516	56283686
Encephalitis fungal	37.85	26.49	6	6859	27	56285175
Chronic graft versus host disease	36.29	26.49	14	6851	3242	56281960
Epstein-Barr virus associated lymphoproliferative disorder	36.23	26.49	12	6853	1791	56283411
Pain	36.12	26.49	18	6847	663166	55622036
Mucosal erosion	35.71	26.49	11	6854	1300	56283902
Cytokine release syndrome	35.62	26.49	20	6845	10855	56274347
Alanine aminotransferase increased	35.35	26.49	50	6815	93612	56191590
Encephalitis Japanese B	35.24	26.49	6	6859	45	56285157
Enterococcal infection	34.31	26.49	17	6848	7167	56278035
Neutropenia	32.19	26.49	64	6801	158103	56127099
Renal impairment	31.81	26.49	44	6821	80669	56204533
Acute respiratory distress syndrome	31.38	26.49	24	6841	21902	56263300
Pleural effusion	31.32	26.49	45	6820	85435	56199767
Trichosporon infection	30.01	26.49	7	6858	285	56284917
Acute lymphocytic leukaemia recurrent	29.66	26.49	11	6854	2286	56282916
Cryptosporidiosis infection	29.30	26.49	7	6858	316	56284886
Acute graft versus host disease in intestine	28.92	26.49	10	6855	1700	56283502
Aspergillus test positive	28.83	26.49	7	6858	339	56284863
Varicella zoster virus infection	28.40	26.49	11	6854	2573	56282629
Fungal sepsis	28.29	26.49	9	6856	1182	56284020
Pneumonia	28.23	26.49	111	6754	406987	55878215
Oral fungal infection	28.17	26.49	11	6854	2629	56282573
Drug ineffective for unapproved indication	28.03	26.49	24	6841	25669	56259533
Fall	27.88	26.49	5	6860	357505	55927697
Mixed liver injury	27.09	26.49	12	6853	3932	56281270
Malaise	26.90	26.49	6	6859	367854	55917348
Liver disorder	26.84	26.49	30	6835	44340	56240862
Rash morbilliform	26.79	26.49	11	6854	2996	56282206

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	202.04	20.14	232	11049	121617	31564446
Aplastic anaemia	192.10	20.14	84	11197	9119	31676944
Acute graft versus host disease in skin	151.45	20.14	59	11222	4773	31681290
Multiple organ dysfunction syndrome	142.70	20.14	147	11134	68056	31618007
Aspergillus infection	141.47	20.14	73	11208	11455	31674608
Bronchopulmonary aspergillosis	140.94	20.14	77	11204	13557	31672506
Candida infection	103.05	20.14	67	11214	16191	31669872
Disseminated intravascular coagulation	97.91	20.14	71	11210	20466	31665597
Herpes simplex oesophagitis	93.46	20.14	20	11261	174	31685889
Cytomegalovirus viraemia	92.45	20.14	46	11235	6679	31679384
Graft versus host disease	89	20.14	52	11229	10395	31675668
Acute graft versus host disease in intestine	86.84	20.14	33	11248	2493	31683570
Acute graft versus host disease	84.32	20.14	42	11239	6111	31679952
Mucormycosis	79.24	20.14	39	11242	5531	31680532
Fungaemia	78.04	20.14	30	11251	2339	31683724
Trichosporon infection	76.94	20.14	22	11259	675	31685388
Fungal infection	68.64	20.14	50	11231	14501	31671562
Cystitis haemorrhagic	66.32	20.14	34	11247	5255	31680808
Venoocclusive liver disease	63.41	20.14	37	11244	7375	31678688
Fusarium infection	63.30	20.14	21	11260	1065	31684998
Cytomegalovirus test positive	62.74	20.14	29	11252	3576	31682487
Product use in unapproved indication	62.47	20.14	120	11161	99051	31587012
Respiratory failure	61.76	20.14	121	11160	101328	31584735
Pyrexia	61.07	20.14	241	11040	303599	31382464
Acute graft versus host disease in liver	54.25	20.14	20	11261	1388	31684675
Sepsis	53.47	20.14	146	11135	151783	31534280
Pre-engraftment immune reaction	52.22	20.14	11	11270	88	31685975
Fatigue	51.09	20.14	28	11253	335178	31350885
Acute myeloid leukaemia recurrent	51.07	20.14	21	11260	1953	31684110
Septic shock	49.13	20.14	86	11195	66072	31619991
Cytomegalovirus infection	47.52	20.14	51	11230	24656	31661407
Systemic candida	47.38	20.14	23	11258	3163	31682900
Cytokine release syndrome	46.25	20.14	42	11239	16600	31669463
Glomerulosclerosis	46.11	20.14	15	11266	715	31685348
Human herpesvirus 6 infection	44.53	20.14	19	11262	1938	31684125
Mucosal inflammation	44.52	20.14	58	11223	34369	31651694
Dizziness	43.47	20.14	9	11272	199138	31486925
Enterococcal infection	43.45	20.14	31	11250	8700	31677363
Chronic graft versus host disease	43.14	20.14	24	11257	4368	31681695
Staphylococcal sepsis	42.18	20.14	31	11250	9106	31676957
Botulism	41.14	20.14	10	11271	160	31685903
Hepatic function abnormal	40.69	20.14	61	11220	41161	31644902
Off label use	39.51	20.14	234	11047	347040	31339023
Encephalitis viral	39.31	20.14	15	11266	1145	31684918
Candida sepsis	38.95	20.14	15	11266	1174	31684889
Pneumonia fungal	37.45	20.14	25	11256	6304	31679759
Drug ineffective	36.65	20.14	253	11028	395320	31290743
Systemic mycosis	35.98	20.14	15	11266	1444	31684619
Haemophagocytic lymphohistiocytosis	35.48	20.14	31	11250	11647	31674416
Thymus hypoplasia	34.63	20.14	9	11272	191	31685872
Lymphoid tissue hypoplasia	34.63	20.14	9	11272	191	31685872
Disseminated aspergillosis	34	20.14	11	11270	515	31685548
Fall	33.86	20.14	12	11269	186077	31499986
Sinusitis fungal	33.30	20.14	11	11270	550	31685513
Cerebral aspergillosis	33.23	20.14	14	11267	1384	31684679
Cholestatic liver injury	31.77	20.14	15	11266	1939	31684124
Bacteraemia	31.47	20.14	35	11246	17599	31668464
Graft versus host disease in gastrointestinal tract	31.43	20.14	18	11263	3461	31682602
Kidney fibrosis	30.68	20.14	15	11266	2095	31683968
Disseminated cryptococcosis	30.27	20.14	13	11268	1347	31684716
Geotrichum infection	30.24	20.14	10	11271	502	31685561
Tumour lysis syndrome	30.00	20.14	32	11249	15353	31670710
Cystitis viral	29.94	20.14	10	11271	518	31685545
Necrotising oesophagitis	29.94	20.14	10	11271	518	31685545
Myocardial infarction	29.64	20.14	3	11278	113451	31572612
Drug resistance	29.51	20.14	39	11242	23414	31662649
Immunosuppressant drug level increased	29.18	20.14	20	11261	5265	31680798
Mucosal disorder	28.77	20.14	13	11268	1521	31684542
Graft versus host disease in skin	28.26	20.14	17	11264	3580	31682483
Idiopathic pneumonia syndrome	28.21	20.14	8	11273	238	31685825
Rhinocerebral mucormycosis	28.03	20.14	9	11272	411	31685652
Delayed graft function	27.44	20.14	14	11267	2141	31683922
Engraft failure	27.40	20.14	9	11272	442	31685621
Platelet count decreased	27.40	20.14	94	11187	110341	31575722
Pseudomembranous colitis	27.21	20.14	15	11266	2680	31683383
Renal failure	27.21	20.14	101	11180	123229	31562834
Product dose omission issue	27.05	20.14	3	11278	105583	31580480
Vascular device infection	26.91	20.14	16	11265	3299	31682764
Klebsiella infection	26.33	20.14	22	11259	7781	31678282
Enterococcal sepsis	25.64	20.14	12	11269	1521	31684542
Reactive gastropathy	25.37	20.14	7	11274	188	31685875
Pseudomonal sepsis	24.84	20.14	15	11266	3181	31682882
Functional gastrointestinal disorder	24.61	20.14	13	11268	2135	31683928
Device related sepsis	24.26	20.14	14	11267	2730	31683333
Ophthalmic vein thrombosis	23.52	20.14	5	11276	42	31686021
Thrombotic microangiopathy	22.89	20.14	22	11259	9329	31676734
Somnolence	22.72	20.14	4	11277	99441	31586622
Liver disorder	22.52	20.14	39	11242	29668	31656395
Infection	22.32	20.14	72	11209	81859	31604204
Bacterial toxaemia	22.27	20.14	6	11275	147	31685916
Depression	22.23	20.14	3	11278	90812	31595251
Antithrombin III decreased	21.99	20.14	7	11274	311	31685752
Haemorrhagic necrotic pancreatitis	21.44	20.14	6	11275	170	31685893
Alternaria infection	21.41	20.14	7	11274	339	31685724
Cerebral ventricle collapse	21.33	20.14	5	11276	68	31685995
Engraftment syndrome	21.26	20.14	9	11272	900	31685163
Arthralgia	21.09	20.14	14	11267	151410	31534653
Weight decreased	20.69	20.14	16	11265	159936	31526127
Blood beta-D-glucan increased	20.36	20.14	7	11274	396	31685667
Neurological symptom	20.31	20.14	14	11267	3717	31682346
Pain in extremity	20.26	20.14	8	11273	116195	31569868
Blood bilirubin increased	20.23	20.14	41	11240	35095	31650968
Blast cell count increased	20.20	20.14	9	11272	1018	31685045
Adenoviral haemorrhagic cystitis	20.18	20.14	7	11274	407	31685656

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	397.37	21.56	354	16679	203964	70707447
Aplastic anaemia	292.13	21.56	120	16913	16596	70894815
Aspergillus infection	228.94	21.56	103	16930	17765	70893646
Multiple organ dysfunction syndrome	222.34	21.56	194	16839	108321	70803090
Pre-engraftment immune reaction	207.78	21.56	40	16993	301	70911110
Bronchopulmonary aspergillosis	201.03	21.56	99	16934	20903	70890508
Human herpesvirus 6 infection	177.67	21.56	60	16973	4799	70906612
Mucormycosis	176.46	21.56	68	16965	7946	70903465
Encephalitis viral	168.51	21.56	49	16984	2393	70909018
Cytomegalovirus viraemia	154.90	21.56	69	16964	11616	70899795
Acute graft versus host disease	148.05	21.56	63	16970	9499	70901912
Candida infection	142.88	21.56	94	16939	34379	70877032
Acute graft versus host disease in skin	130.66	21.56	53	16980	7084	70904327
Sepsis	130.06	21.56	220	16813	244325	70667086
Product use in unapproved indication	121.52	21.56	195	16838	207283	70704128
Disseminated intravascular coagulation	121.04	21.56	84	16949	33514	70877897
Fungaemia	113.10	21.56	41	16992	4041	70907370
Trichosporon infection	111.43	21.56	29	17004	932	70910479
Cytomegalovirus infection	108.37	21.56	84	16949	39674	70871737
Fungal infection	108.36	21.56	82	16951	37385	70874026
Systemic candida	104.98	21.56	43	16990	5891	70905520
Graft versus host disease	104.01	21.56	57	16976	14966	70896445
Pyrexia	100.95	21.56	347	16686	606605	70304806
Respiratory failure	97.93	21.56	158	16875	168577	70742834
Hepatic function abnormal	97.76	21.56	100	16933	67896	70843515
Septic shock	95.54	21.56	126	16907	112132	70799279
Pneumonia fungal	95.45	21.56	47	16986	9906	70901505
Cytomegalovirus test positive	90.96	21.56	38	16995	5470	70905941
Herpes simplex oesophagitis	88.81	21.56	20	17013	343	70911068
Acute graft versus host disease in intestine	86.21	21.56	33	17000	3783	70907628
Fatigue	84.05	21.56	47	16986	824272	70087139
Enterococcal infection	78.61	21.56	47	16986	14535	70896876
Cytokine release syndrome	74.47	21.56	57	16976	26410	70885001
Systemic mycosis	72.37	21.56	26	17007	2496	70908915
Venoocclusive liver disease	69.76	21.56	39	16994	10639	70900772
Platelet count decreased	69.00	21.56	140	16893	178082	70733329
Geotrichum infection	68.40	21.56	20	17013	995	70910416
Acute myeloid leukaemia recurrent	67.52	21.56	26	17007	3028	70908383
Arthralgia	67.03	21.56	19	17014	503371	70408040
Haemophagocytic lymphohistiocytosis	65.89	21.56	47	16986	19565	70891846
Disseminated aspergillosis	63.37	21.56	18	17015	807	70910604
Pathogen resistance	61.88	21.56	39	16994	13240	70898171
Mucosal inflammation	58.99	21.56	77	16956	67773	70843638
Fall	58.67	21.56	17	17016	444079	70467332
Off label use	58.41	21.56	340	16693	742720	70168691
Pain	58.23	21.56	40	16993	628776	70282635
Fusarium infection	57.89	21.56	20	17013	1712	70909699
Drug ineffective	57.88	21.56	404	16629	939348	69972063
Meningoencephalitis herpetic	56.71	21.56	20	17013	1819	70909592
Bacterial sepsis	55.66	21.56	30	17003	7617	70903794
Dizziness	55.65	21.56	21	17012	464120	70447291
Lymphoid tissue hypoplasia	54.93	21.56	15	17018	581	70910830
Drug resistance	54.56	21.56	56	16977	38134	70873277
Thymus hypoplasia	53.90	21.56	15	17018	624	70910787
Enterococcal sepsis	53.80	21.56	21	17012	2536	70908875
Acute graft versus host disease in liver	53.41	21.56	19	17014	1773	70909638
Cystitis haemorrhagic	52.39	21.56	30	17003	8563	70902848
Candida sepsis	51.89	21.56	20	17013	2335	70909076
Chronic graft versus host disease	50.51	21.56	27	17006	6743	70904668
Headache	49.74	21.56	40	16993	580365	70331046
Disseminated cryptococcosis	49.69	21.56	18	17015	1769	70909642
Tumour lysis syndrome	49.39	21.56	41	16992	21319	70890092
Bacteraemia	49.33	21.56	47	16986	29262	70882149
Hypoalbuminaemia	49.06	21.56	39	16994	19083	70892328
Pneumonia	48.84	21.56	276	16757	595956	70315455
Engraft failure	48.82	21.56	14	17019	650	70910761
Aspartate aminotransferase increased	48.22	21.56	99	16934	126879	70784532
Blood bilirubin increased	47.49	21.56	65	16968	59836	70851575
Thrombotic microangiopathy	47.07	21.56	37	16996	17811	70893600
Gastrointestinal fungal infection	46.40	21.56	12	17021	376	70911035
Cerebral aspergillosis	46.27	21.56	17	17016	1739	70909672
Staphylococcal sepsis	44.69	21.56	32	17001	13395	70898016
Liver abscess	43.67	21.56	23	17010	5576	70905835
Malaise	43.52	21.56	25	17008	432907	70478504
Renal failure	43.18	21.56	121	16912	188949	70722462
Weissella infection	42.72	21.56	7	17026	17	70911394
Acute respiratory distress syndrome	42.53	21.56	51	16982	41203	70870208
Alanine aminotransferase increased	42.51	21.56	103	16930	147377	70764034
Nasopharyngitis	41.80	21.56	3	17030	222203	70689208
Pseudomonal sepsis	41.08	21.56	22	17011	5515	70905896
Cholestatic liver injury	40.91	21.56	20	17013	4148	70907263
Product dose omission issue	40.72	21.56	3	17030	217465	70693946
Renal impairment	39.86	21.56	99	16934	143838	70767573
Peripheral swelling	39.74	21.56	5	17028	236558	70674853
Glomerulosclerosis	39.43	21.56	13	17020	964	70910447
Sinus polyp	39.40	21.56	11	17022	463	70910948
Pain in extremity	39.03	21.56	15	17018	328067	70583344
Pleural effusion	38.51	21.56	93	16940	132771	70778640
White blood cell count decreased	37.97	21.56	108	16925	170033	70741378
Botulism	37.14	21.56	10	17023	367	70911044
Mucosal disorder	36.43	21.56	17	17016	3181	70908230
Alopecia	36.43	21.56	3	17030	198487	70712924
Neutrophil count decreased	36.36	21.56	69	16964	83487	70827924
Bacterial infection	36.31	21.56	38	16995	26454	70884957
Engraftment syndrome	36.15	21.56	13	17020	1251	70910160
Delayed graft function	35.86	21.56	17	17016	3296	70908115
Cystitis viral	35.48	21.56	11	17022	669	70910742
Blast cell count increased	35.44	21.56	13	17020	1324	70910087
Drug intolerance	35.06	21.56	6	17027	225681	70685730
Acute lymphocytic leukaemia recurrent	35.02	21.56	19	17014	4885	70906526
Asthenia	35.02	21.56	35	16998	457631	70453780
Necrotising oesophagitis	34.96	21.56	11	17022	702	70910709
Nasal abscess	34.85	21.56	8	17025	150	70911261
Immunosuppressant drug level increased	33.81	21.56	22	17011	7885	70903526
Mixed liver injury	33.31	21.56	20	17013	6229	70905182
Idiopathic pneumonia syndrome	33.14	21.56	10	17023	555	70910856
Acute myeloid leukaemia	33.12	21.56	39	16994	30901	70880510
Weight increased	32.47	21.56	9	17024	242322	70669089
Dyspnoea	31.85	21.56	88	16945	769972	70141439
Graft versus host disease in gastrointestinal tract	31.62	21.56	19	17014	5925	70905486
Pulmonary mucormycosis	31.54	21.56	11	17022	968	70910443
Vascular device infection	31.08	21.56	21	17012	8009	70903402
Neutropenia	30.94	21.56	133	16900	257023	70654388
Staphylococcal infection	30.90	21.56	50	16983	53354	70858057
Cytomegalovirus enterocolitis	30.57	21.56	12	17021	1471	70909940
Rhinocerebral mucormycosis	30.27	21.56	10	17023	746	70910665
Klebsiella infection	30.10	21.56	26	17007	14266	70897145
Graft versus host disease in skin	29.96	21.56	18	17015	5612	70905799
Enterobacter infection	29.75	21.56	16	17017	4044	70907367
Lymphocyte count decreased	29.72	21.56	44	16989	43495	70867916
Biloma	29.61	21.56	7	17026	150	70911261
Graft versus host disease in liver	29.56	21.56	12	17021	1606	70909805
Depression	29.38	21.56	6	17027	198968	70712443
Adenovirus infection	29.32	21.56	20	17013	7748	70903663
Pruritus	29.31	21.56	24	17009	345536	70565875
Encephalitis Japanese B	28.95	21.56	6	17027	68	70911343
Device related infection	28.69	21.56	37	16996	32148	70879263
Oesophagitis	28.41	21.56	31	17002	22621	70888790
Nephropathy toxic	27.99	21.56	28	17005	18486	70892925
Rash morbilliform	27.89	21.56	17	17016	5438	70905973
Plasma cell leukaemia	27.87	21.56	12	17021	1859	70909552
Epstein-Barr virus infection	27.77	21.56	24	17009	13174	70898237
Staphylococcal bacteraemia	27.14	21.56	22	17011	11060	70900351
Mucosal erosion	26.60	21.56	12	17021	2077	70909334
Drug hypersensitivity	26.56	21.56	15	17018	262444	70648967
Hypersensitivity	26.50	21.56	11	17022	229801	70681610
Pseudomembranous colitis	26.32	21.56	16	17017	5095	70906316
Neutropenic colitis	26.31	21.56	16	17017	5098	70906313
Toxicity to various agents	26.17	21.56	32	17001	382140	70529271
Chest pain	25.95	21.56	14	17019	251246	70660165
Cytopenia	25.82	21.56	26	17007	17297	70894114
Blood pressure increased	25.25	21.56	7	17026	188510	70722901
Blood urea increased	25.23	21.56	42	16991	45867	70865544
Drug-induced liver injury	25.23	21.56	47	16986	56066	70855345
Abdominal discomfort	25.20	21.56	10	17023	214648	70696763
Gait disturbance	24.55	21.56	7	17026	185099	70726312
Liver disorder	24.53	21.56	49	16984	61519	70849892
Bacterial toxaemia	24.23	21.56	6	17027	157	70911254
Kidney fibrosis	24.17	21.56	13	17020	3287	70908124
Clostridium difficile colitis	23.79	21.56	32	17001	28964	70882447
Drug ineffective for unapproved indication	23.55	21.56	37	16996	38501	70872910
Sinusitis fungal	23.49	21.56	11	17022	2074	70909337
Hypokalaemia	23.38	21.56	77	16956	131111	70780300
Leukaemia recurrent	23.36	21.56	12	17021	2763	70908648
Platelet transfusion	23.33	21.56	11	17022	2107	70909304
Candida test positive	23.20	21.56	9	17024	1069	70910342
Pulmonary haemorrhage	23.14	21.56	22	17011	13651	70897760
Brain abscess	22.76	21.56	14	17019	4552	70906859
Aspergillus test positive	22.70	21.56	8	17025	726	70910685
Device related sepsis	22.22	21.56	15	17018	5713	70905698
Gamma-glutamyltransferase increased	22.22	21.56	42	16991	50643	70860768
Reactive gastropathy	21.98	21.56	7	17026	465	70910946
Oral disorder	21.93	21.56	18	17015	9211	70902200
Blood lactate dehydrogenase increased	21.85	21.56	34	16999	35093	70876318
Myocardial infarction	21.84	21.56	7	17026	171638	70739773
Hyperbilirubinaemia	21.79	21.56	27	17006	22541	70888870
Viral haemorrhagic cystitis	21.69	21.56	10	17023	1821	70909590
Oral fungal infection	21.66	21.56	12	17021	3214	70908197

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J02AX05	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE Other antimycotics for systemic use
FDA CS	M0519359	Lipopeptides
FDA EPC	N0000175507	Echinocandin Antifungal
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000935	Antifungal Agents
CHEBI has role	CHEBI:35441	antiinfective agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Candidiasis of the esophagus	indication	20639004	DOID:13146
Disseminated candidiasis	indication	70572005
Candidal septicemia	indication	187022007
Candidemia	indication	432261003
Prevention of Disseminated Candidiasis	indication
Candida Peritonitis	indication
Oropharyngeal Candidiasis	off-label use
Intravascular hemolysis	contraindication	15601008
Kidney disease	contraindication	90708001	DOID:557
Liver function tests abnormal	contraindication	166603001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.09	acidic
pKa2	10.7	acidic
pKa3	12.91	acidic
pKa4	13.44	acidic
pKa5	13.52	acidic
pKa6	13.9	acidic
pKa7	13.91	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 100MG BASE/VIAL	MYCAMINE	ASTELLAS	N021506	June 27, 2006	RX	INJECTABLE	INTRAVENOUS	Dec. 20, 2022	TREATMENT OF CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES WITHOUT MENINGOENCEPHALITIS AND/OR OCULAR DISSEMINATION IN PEDIATRIC PATIENTS YOUNGER THAN 4 MONTHS OF AGE
EQ 50MG BASE/VIAL	MYCAMINE	ASTELLAS	N021506	March 16, 2005	RX	INJECTABLE	INTRAVENOUS	Dec. 20, 2022	TREATMENT OF CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES WITHOUT MENINGOENCEPHALITIS AND/OR OCULAR DISSEMINATION IN PEDIATRIC PATIENTS YOUNGER THAN 4 MONTHS OF AGE
EQ 100MG BASE/VIAL	MYCAMINE	ASTELLAS	N021506	June 27, 2006	RX	INJECTABLE	INTRAVENOUS	June 20, 2023	PEDIATRIC EXCLUSIVITY
EQ 50MG BASE/VIAL	MYCAMINE	ASTELLAS	N021506	March 16, 2005	RX	INJECTABLE	INTRAVENOUS	June 20, 2023	PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Beta-1,3-glucan synthase catalytic subunit 1	Enzyme		O13428_CANAX	INHIBITOR				CHEMBL	CHEMBL
Beta-1,3-glucan synthase	Unclassified		Q5AIC4_CANAL					WOMBAT-PK

External reference:

ID	Source
D02465	KEGG_DRUG
208538-73-2	SECONDARY_CAS_RN
4024920	VANDF
4024948	VANDF
C1120386	UMLSCUI
CHEBI:600520	CHEBI
CHEMBL1237070	ChEMBL_ID
CHEMBL457547	ChEMBL_ID
D000077551	MESH_DESCRIPTOR_UI
DB01141	DRUGBANK_ID
8069	INN_ID
R10H71BSWG	UNII
477468	PUBCHEM_CID
325887	RXNORM
19567	MMSL
334346	MMSL
66902	MMSL
d05487	MMSL
010714	NDDF
010715	NDDF
416127003	SNOMEDCT_US
416233001	SNOMEDCT_US
426226002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9361	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	ANDA	27 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9362	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	ANDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3211	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	NDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3211	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	NDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3211	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	NDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3211	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	NDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3211	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	NDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3250	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	NDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3250	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	NDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3250	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	NDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3250	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	NDA	27 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	25021-190	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	ANDA	29 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	25021-190	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	ANDA	29 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	25021-191	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	29 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	25021-191	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	29 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	42023-229	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	NDA	26 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	42023-230	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	NDA	26 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6119	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	ANDA	27 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6120	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	ANDA	27 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	63323-728	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	ANDA	30 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	63323-728	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	ANDA	30 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	63323-729	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	30 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	63323-729	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	30 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	63323-729	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	30 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	70594-036	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	ANDA	34 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	70594-037	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	ANDA	34 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	71288-028	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	ANDA	30 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	71288-029	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	30 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	72572-427	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	34 sections